MD Anderson Cancer Center
Cancer Drug Shortage Is Costing Lives – CNL
Acute myelogenous leukemia (AML) is a fast-progressing cancer that typically takes a patient’s life within two to three months if not treated quickly and properly. Cytarabine is the only known drug to affectively treat AML, having a survival rate of 40% to 50%. Without cytarabine, the survival rate is 0%. The number of drugs, including those used to treat cancer, that are in short supply within the United States has tripled since 2005. Hagop Kantarjian, M.D., chair of the Department of Leukemia at MD Anderson Cancer Center, speaks out on this topic.
Loading the Audio Player...

Title: Cancer Drug Shortage Is Costing Lives – CNL
Summary: Acute myelogenous leukemia (AML) is a fast-progressing cancer that typically takes a patient’s life within two to three months if not treated quickly and properly. Cytarabine is the only known drug to affectively treat AML, having a survival rate of 40% to 50%. Without cytarabine, the survival rate is 0%. The number of drugs, including those used to treat cancer, that are in short supply within the United States has tripled since 2005. Hagop Kantarjian, M.D., chair of the Department of Leukemia at MD Anderson Cancer Center, speaks out on this topic.
Keywords: Cancer Newsline, CNL, Drug, shortage, cancer, cytarabine, acute myelogenous leukemia, aml, Hagop Kantarjian
Transcript: